IFIH1-Related Type 1 Interferonopathy

Disease-knowledge-base research report — evidence reviewed through 15 October 2026

Executive summary

IFIH1-related type 1 interferonopathy (MONDO:0700262) is a rare, autosomal-dominant Mendelian immune-dysregulation disorder caused principally by heterozygous germline gain-of-function (GOF) variants in IFIH1, encoding the cytosolic double-stranded-RNA sensor MDA5. It is best understood as one continuous, variably penetrant disease spectrum encompassing Aicardi–Goutières syndrome type 7 (AGS7), neuroregression/spastic-dystonic and spastic-paraparetic phenotypes, Singleton–Merten syndrome type 1 (SMS1), lupus-like or organ-predominant inflammation, and clinically asymptomatic carriers with an elevated interferon signature. The ClinGen/GenCC-style 2024 evaluation classifies the IFIH1–disease relationship as definitive and deliberately “lumps” AGS7 and SMS1 under MONDO:0700262. GenCC submission, 23 August 2024, URL [64][69]

The largest dedicated cohort comprised 74 variant-positive people from 51 families with 27 likely pathogenic variants. Ten carriers (13.5%) were clinically asymptomatic, including seven older than 50 years, demonstrating incomplete penetrance; nevertheless, nearly all tested variants or carriers showed elevated type-I-interferon signaling. Rice et al., Human Mutation, published online 14 January 2020, PMID: 31898846 [31][39]

Key primary-literature quote: “We identified 74 individuals from 51 families segregating a total of 27 likely pathogenic mutations in IFIH1.” [PMID: 31898846] [31]

There is no approved disease-specific curative therapy. Off-label JAK1/2 inhibition—particularly baricitinib or ruxolitinib—is the leading targeted strategy. It can suppress the interferon signature and improve inflammatory, skin, systemic, and sometimes developmental outcomes, but reversal of established brain injury is uncertain and infections and cytopenias are important risks. Vanderver et al., NEJM, 3 September 2020 [155]

1. Disease information

1.1 Definition and scope

IFIH1-related type 1 interferonopathy is a monogenic autoinflammatory/autoimmune disorder of innate nucleic-acid sensing. Constitutively or excessively active MDA5 produces inappropriate type-I-interferon signaling in the absence of an adequate viral threat. The resulting phenotype ranges from prenatal or infantile encephalopathy to later spastic paraparesis, vascular/dental/skeletal calcific disease, isolated inflammatory manifestations, or biochemical nonpenetrance.

The umbrella concept is preferable to treating AGS7 and SMS1 as unrelated disorders because:

1. both result from monoallelic IFIH1 GOF;
2. neurological, cutaneous, skeletal, dental, and vascular phenotypes overlap;
3. the same variant may produce markedly different disease within a family; and
4. elevated interferon-stimulated gene expression is a shared biological feature. [33][64]

1.2 Identifiers and names

Synonyms: IFIH1 gain-of-function disease; MDA5 gain-of-function disease; MDA5-associated interferonopathy; IFIH1-associated autoinflammation; AGS7; Aicardi–Goutières syndrome due to IFIH1; Singleton–Merten syndrome 1; IFIH1-related Singleton–Merten dysplasia.

1.3 Evidence granularity

This report is based primarily on aggregated disease-level resources and published cohorts, supplemented by individual case reports and pedigrees. It is not derived from a single patient’s EHR. A 2024 real-world/natural-history analysis included 19 IFIH1-positive patients among 167 molecularly diagnosed AGS patients, but those data concern genetically heterogeneous AGS and should not automatically be generalized to every IFIH1 carrier. [138]

2. Etiology

2.1 Primary cause

The established cause is a heterozygous constitutional GOF variant in IFIH1. Most confirmed variants are missense substitutions in or near the MDA5 helicase/ATP- and RNA-interacting regions. A 2024 report expanded the mechanism to an in-frame deletion, p.Glu794del, showing that not every pathogenic GOF allele is missense. MDA5 p.Glu794del report, 2 October 2024 [76]

GOF can result from:

• increased affinity for endogenous or viral dsRNA;
• constitutive or reduced-threshold signaling;
• impaired ATP hydrolysis;
• slower MDA5 filament disassembly;
• prolonged MAVS activation.

2.2 Genetic risk factors

Common IFIH1 polymorphisms influence polygenic autoimmunity and antiviral responses, but these susceptibility associations are not equivalent to monogenic GOF interferonopathy. Conversely, monoallelic or biallelic loss-of-function can predispose to viral disease/immunodeficiency and should not be classified as the same mechanism. [44]

2.3 Environmental and infectious risk factors

No toxin, diet, occupation, smoking exposure, alcohol exposure, or lifestyle behavior is established as a primary cause.

Infection or dsRNA exposure is a biologically plausible disease modifier. In an MDA5-R822Q mouse model, poly(I:C), a synthetic dsRNA analogue, sharply exacerbated inflammation and mortality; deleting MAVS or IFNAR prevented this enhancement. This is strong model-organism evidence for gene–immune-trigger interaction but not proof that a particular human virus initiates disease. [121][126]

Clinical neuroregression can occur after apparently normal development and may appear temporally associated with febrile illness, but published evidence does not establish one infectious agent as necessary or sufficient.

2.4 Protective factors

No validated environmental protective factor exists.

Potential genetic/biological protection is inferred from:

• alleles that reduce MDA5 signaling, known to protect against some autoimmune phenotypes in population studies;
• unidentified modifier genes in unaffected GOF carriers;
• intact negative regulators of MDA5–MAVS and IFNAR signaling.

These are mechanistic hypotheses, not clinically actionable protective genotypes. Routine deliberate infection avoidance beyond standard care, special diets, or supplements have not been proven to prevent onset.

3. Phenotypes

Phenotypic frequency estimates are limited by ascertainment bias toward pediatric neurological disease. In the 74-person cohort, at least 20 had unequivocal rapid neuroregression, ten were clinically asymptomatic, and six symptomatic patients had died. Imaging findings were not systematically recorded, so precise percentages are unavailable. [39]

3.1 Phenotype catalogue

The core SMS phenotype comprises aortic/valvular calcification, delayed eruption and abnormal root formation, early permanent-tooth loss, osteoporosis and acro-osteolysis; glaucoma, psoriasis, muscle weakness and joint laxity are less consistent. [167][179]

No disease-specific validated EQ-5D, SF-36 or PROMIS dataset was found. Quality-of-life effects must therefore be inferred from neurological dependence, communication impairment, recurrent inflammatory symptoms, dental loss, cardiopulmonary disease and caregiver burden.

4. Genetic and molecular information

4.1 Gene and protein

These identifiers are supported by NCBI Gene and UniProt. [46][47][49]

4.2 Pathogenic variant spectrum

All variants in the landmark cohort were germline/constitutional and heterozygous. Population frequencies were absent or ultra-rare. Do not infer benignity solely from computational prediction: six of 27 variants, 22%, were called benign by multiple in-silico tools despite functional/biomarker evidence of GOF. [31]

Full cohort source: Rice et al., PMID: 31898846 [39].

ACMG interpretation: classifications vary by ClinVar submitter and date. A rare missense or in-frame variant should generally require segregation/de novo evidence, a compatible phenotype, blood interferon signature and preferably a validated IFNβ reporter, RNA-binding, ATPase or filament assay. A negative family history is weak counter-evidence because both de novo disease and nonpenetrance are common.

4.3 Other genomic features

• Structural variants/chromosomal abnormalities: no recurrent CNV, translocation, inversion or aneuploidy is established as the characteristic cause.
• Somatic disease: the recognized disorder is germline; postzygotic parental mosaicism is relevant to recurrence. Disease-causing somatic-only IFIH1 GOF is not established as a major category.
• Epigenetics: no reproducible disease-specific methylation episignature or causal chromatin defect has been validated.
• Modifier genes: none conclusively identified.
• Anticipation/founder effect: no evidence for repeat-associated anticipation or a major founder allele.
• Consanguinity: not a risk factor for dominant GOF disease, although it is relevant when considering recessive AGS genes or IFIH1 loss-of-function immunodeficiency.

5. Environmental information

The correct knowledge-base representation is therefore genetic cause with possible infection/innate-immune-stimulation modifiers, not a communicable or environmentally acquired disease.

6. Mechanism and pathophysiology

6.1 Ordered causal chain

1. A heterozygous IFIH1 GOF variant leads to an MDA5 receptor with increased RNA affinity, increased basal activity, impaired ATP-driven turnover, or reduced filament disassembly.
2. Abnormally stable or readily formed MDA5–dsRNA filaments lead to excessive oligomerization of MDA5 CARD domains.
3. CARD oligomerization leads to persistent activation of mitochondrial antiviral-signaling protein MAVS on the outer mitochondrial membrane.
4. MAVS activation leads to recruitment of TBK1/IKKε and activation of IRF3/IRF7, with a parallel NF-κB inflammatory branch. Reactome R-HSA-168928 [58]
5. IRF3/IRF7 and NF-κB activation leads to inappropriate transcription and secretion of IFN-β, IFN-α and inflammatory cytokines.
6. Type-I IFN binding to IFNAR1/IFNAR2 leads to JAK1/TYK2 activation and STAT1/STAT2–IRF9 signaling.
7. JAK–STAT signaling leads to sustained expression of interferon-stimulated genes including IFI27, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1.
8. Sustained interferon signaling leads to immune-cell activation, endothelial and tissue inflammation, altered cell survival and developmental neurotoxicity.
9. In the central-nervous-system branch, chronic prenatal/infantile inflammation leads to white-matter injury, calcification and cerebral atrophy, resulting in developmental delay, regression, dystonia and spasticity. The exact cell-autonomous contribution of neurons versus glia is partly inferred rather than fully demonstrated in human tissue.
10. In the vascular–skeletal–dental branch, chronic MDA5/IFN inflammation leads to dysregulated mineralization and remodeling, resulting in aortic/valvular calcification, osteopenia, acro-osteolysis and abnormal tooth roots/loss. The intermediate mineralization mechanisms remain incompletely resolved.
11. In systemic branches, immune dysregulation leads to chilblains, psoriasis-like disease, hepatitis, lupus-like autoimmunity, thyroid disease, pulmonary vascular disease or organ-limited inflammation.
12. Modifier genes and immune exposures are inferred to alter threshold and tissue distribution, producing incomplete penetrance and extreme variable expressivity.

6.2 Upstream and downstream processes

Upstream: MDA5 RNA recognition, ATP binding/hydrolysis and filament dynamics.
Intermediate: MAVS, TBK1/IKKε, IRF3/7, NF-κB, IFN secretion.
Downstream: IFNAR–JAK1/TYK2–STAT1/2–IRF9, ISG expression, chronic inflammation and tissue injury.

Suggested GO biological-process terms:

• GO:0009615 response to virus
• GO:0003725 double-stranded RNA binding
• GO:0039528 cytoplasmic pattern-recognition receptor signaling pathway in response to virus
• GO:0032481 positive regulation of type I interferon production
• GO:0060337 type I interferon signaling pathway
• GO:0045087 innate immune response
• GO:0006954 inflammatory response
• GO:0002250 adaptive immune response
• GO:0043065 positive regulation of apoptotic process, where experimentally supported
• GO:0001503 ossification/mineralization-related processes for the SMS branch, presently less direct

Suggested GO cellular-component terms:

• GO:0005829 cytosol
• GO:0005739 mitochondrion
• GO:0005741 mitochondrial outer membrane
• GO:0005634 nucleus
• GO:0031514 motile cilium is not a primary compartment and should not be assigned.

6.3 Cells implicated

6.4 Molecular profiling and advanced technologies

The validated clinical transcriptomic feature is the whole-blood ISG signature. In the 2020 cohort, 109/117 measurements from 51 mutation-positive people were elevated; 16 samples from seven clinically unaffected carriers were also positive. The six-gene score used IFI27, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1. [39]

No validated disease-specific human:

• single-cell atlas,
• spatial-transcriptomic map,
• proteomic signature,
• metabolomic or lipidomic signature,
• or integrated multi-omic clinical classifier

was identified. The absence of these data should be encoded as “not established,” rather than as a negative finding.

7. Anatomical structures affected

Neurological disease is generally bilateral/diffuse, but unilateral white-matter disease is documented; therefore lateralization is variable rather than defining. [39]

8. Temporal development

• Prenatal/congenital severe disease: five of six deaths in the 74-person cohort involved severe AGS evident at or shortly after birth, implying prenatal inflammation.
• Classic postnatal AGS pattern: apparently normal early development followed by subacute irritability, fever and loss of milestones in infancy.
• Later regression: seven patients lost skills after age one despite normal prior development.
• Spastic-paraparetic pattern: insidious, slowly progressive childhood or adolescent disease; onset as late as 13 years was documented.
• SMS pattern: dental and skeletal abnormalities evolve in childhood; aortic/valvular calcification may progress through childhood or puberty.
• Clinically silent state: can persist beyond age 50 despite a pathogenic allele and sometimes elevated ISGs.

The active encephalopathic phase may be followed by relative neurological stabilization, but fixed disability remains. Spastic paraparesis and vascular/skeletal disease may continue to progress. Spontaneous molecular remission is not characterized. Earlier suppression of interferon signaling is biologically more likely to prevent injury than to reverse calcification, atrophy or established leukodystrophy.

9. Inheritance and population

More than 500 AGS patients of all molecular subtypes have been described, but this is not an IFIH1 prevalence estimate. [136] In one Italian molecular cohort IFIH1 accounted for 11–12% of AGS, versus approximately 3% in an earlier international cohort; this variation likely reflects ascertainment and small samples rather than true geographic prevalence. [141]

10. Diagnostics

10.1 Practical diagnostic pathway

1. Recognize the spectrum: congenital-infection-like disease without infection, infantile neuroregression, unexplained spastic-dystonia/paraparesis, intracranial calcification/leukodystrophy, chilblains, or early aortic/dental/skeletal disease.
2. Exclude urgent acquired mimics, particularly congenital or CNS infection.
3. Measure a peripheral-blood type-I-interferon signature, preferably before immunosuppression and repeated if suspicion remains high.
4. Perform molecular testing using an interferonopathy/AGS panel or exome/genome sequencing.
5. Confirm and phase the variant by parental testing; assess low-level mosaicism if recurrence or sibling disease is unexplained.
6. Use functional validation for novel/VUS alleles: IFNβ reporter assay, basal/poly(I:C)-stimulated signaling, RNA binding, ATPase activity or filament turnover.
7. Stage organ involvement with brain imaging, cardiac/vascular, dental, ophthalmic and laboratory assessment.

10.2 Clinical tests

10.3 Genetic testing modalities

A normal parental phenotype does not establish that a familial variant is benign. Test both parents molecularly and, if indicated, assess their interferon signatures.

10.4 Differential diagnosis

No universally accepted stand-alone clinical diagnostic criteria exist; diagnosis is clinicomolecular.

10.5 Screening

• No population or newborn screening program exists.
• Cascade testing is recommended for first-degree relatives once a pathogenic variant is found.
• Test apparently unaffected relatives because of incomplete penetrance.
• Surveillance is preferable to assuming lifelong safety in a genotype-positive relative.
• Reproductive options include prenatal diagnosis and PGT-M after genetic counseling.

11. Outcomes and prognosis

No reliable 5- or 10-year survival statistic is available.

In the largest IFIH1 cohort, six symptomatic patients died: five had severe disease apparent at or soon after birth, and one developed regression at 15 months and died at age 16 from sudden cardiorespiratory arrest with pulmonary hypertension found at autopsy. [39][143]

Important morbidity includes:

• severe intellectual and motor disability;
• dystonia, spasticity and contractures;
• feeding and communication impairment;
• visual impairment;
• progressive dental loss;
• osteoporosis and skeletal deformity;
• aortic or valve stenosis/calcification;
• chronic skin disease;
• autoimmune organ disease;
• treatment-related infection and cytopenia.

Poor prognostic indicators: prenatal/congenital presentation, early rapid regression, severe microcephaly, extensive atrophy/white-matter disease, cardiopulmonary disease, and delayed control of active inflammation.

Relatively favorable indicators: later isolated paraparesis, preserved cognition, absence of structural CNS injury and sustained response to pathway-directed therapy. These are descriptive rather than validated predictors.

The blood ISG score is a pharmacodynamic biomarker, but its quantitative value as a long-term prognostic marker is not established; asymptomatic carriers may have persistently high scores.

12. Treatment

12.1 Treatment status and algorithm

There is no approved IFIH1-corrective treatment and no evidence-based surgical cure. A reasonable expert pathway is:

1. document active disease and baseline ISG score;
2. treat urgent organ complications;
3. consider early JAK-pathway inhibition for progressive neurological, cutaneous or systemic inflammation;
4. provide multidisciplinary rehabilitation and organ-specific surveillance;
5. monitor CBC, liver and renal function, lipids, infections and IFN signature;
6. continue cardiac, dental, ophthalmic and bone surveillance even if inflammatory symptoms improve.

12.2 Pharmacological and supportive interventions

Before and during JAK inhibition, screen for tuberculosis and hepatitis as locally recommended, update non-live vaccines where possible, and monitor infection, CBC, hepatic/renal function and thrombosis risk. Live-vaccine decisions require specialist assessment.

12.3 Clinical trials

No IFIH1-directed gene replacement, CRISPR editing, ASO, siRNA or cell therapy is in established clinical use. Because disease is dominant GOF, successful genetic therapy would likely require allele-specific silencing or correction rather than simple gene addition.

13. Prevention

Primary prevention

The occurrence of a de novo mutation cannot currently be prevented by lifestyle modification. For known familial disease:

• genetic counseling;
• PGT-M;
• chorionic-villus or amniotic-fluid prenatal diagnosis;
• donor gametes or other reproductive options

can reduce recurrence according to family preferences.

Secondary prevention

• Cascade-test relatives.
• Establish baseline neurological, cardiac, dental, bone, eye and laboratory status.
• Repeat ISG measurement and organ surveillance where appropriate.
• Treat active inflammation early, before fixed CNS or vascular injury develops.

Tertiary prevention

• contracture, aspiration and pressure-injury prevention;
• nutrition and swallowing management;
• infection precautions during JAK inhibition;
• dental hygiene and periodontal follow-up;
• fracture prevention and vitamin-D/calcium adequacy;
• serial echocardiography and vascular assessment;
• glaucoma surveillance;
• psychosocial, educational and communication support.

Routine vaccination remains important, particularly before immunosuppression. There is no IFIH1-specific vaccine or antimicrobial prophylaxis. Live vaccines may be contraindicated or deferred during significant JAK inhibition according to local guidance.

14. Other species and natural disease

No well-validated naturally occurring companion-animal or livestock equivalent caused by spontaneous IFIH1 GOF was identified in OMIA. The disorder is not infectious and has no zoonotic or cross-species transmission risk.

MDA5-dependent dsRNA sensing is evolutionarily conserved among jawed vertebrates, but species differ in interferon development, ligand exposure and tissue response. Consequently, animal models often reproduce systemic inflammation better than human neurological disability.

15. Model organisms

2023 model-paper quote: RNA sequencing of mutant zebrafish “revealed a systemic inflammation and IFN signature upon a suboptimal poly I:C induction compared with wild-type larvae.” [Bernal-Bermúdez et al., Frontiers in Immunology, 24 November 2023, PMID: 38077314] [106]

Model resources include MGI/IMSR/MMRRC for mouse alleles—mouse Ifih1 is MGI:1918836 and an Ifih1 resource is listed by MMRRC—and ZFIN for zebrafish lines and publications. [56][96][120]

Evidence appraisal and knowledge gaps

High-confidence conclusions

• Definitive causal relationship between monoallelic IFIH1 GOF and MONDO:0700262.
• AD inheritance with frequent de novo occurrence.
• Mechanistic activation of MDA5–MAVS–type-I-IFN signaling.
• Very broad expressivity and incomplete penetrance.
• Blood ISG expression is a strong diagnostic and pharmacodynamic biomarker.
• AGS7 and SMS1 represent overlapping ends of one disease spectrum.

Moderate-confidence conclusions

• Viral or dsRNA stimulation can modify severity.
• Early JAK inhibition can improve inflammatory disease and perhaps permit developmental gains.
• Specific neural and mineralizing cell populations mediate tissue injury.

Major unresolved questions

• True population prevalence, incidence and sex ratio.
• Why some carriers remain well despite persistent IFN signaling.
• Robust genotype–phenotype correlations.
• Optimal JAK inhibitor, dose, initiation age and treatment duration.
• Whether pre-symptomatic treatment prevents CNS or vascular damage.
• Disease-specific quality-of-life and long-term survival data.
• Human single-cell/spatial maps and validated proteomic/metabolomic biomarkers.
• Safe allele-specific RNA or genome-directed therapy.

The most important practical interpretation is that a rare IFIH1 variant must be evaluated in the joint context of phenotype, inheritance, interferon signature and functional signaling—not by computational pathogenicity prediction alone.

Reference Validation

Checked with linkml-reference-validator 0.3.0.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• DOI:10.1007/s12688-026-00957-1 (1 mention) - Januskinase-Inhibitoren bei Interferonopathien
• shared terms: none

Weighed against this report's own most characteristic terms: disease, ifih1, gof, established, ags, variant, mda5, dental, phenotype, inflammation, cohort, signaling, interferon, gene, signature, ifn, calcification, inflammatory, infection, skeletal.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• UBERON:0002048 (1 mention) - the report calls it "Lung/pulmonary vasculature"; UBERON calls it lung
• UBERON:0000970 (1 mention) - the report calls it "Eye/anterior chamber"; UBERON calls it eye

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0039528 (GO_0039528) (1 mention) - replaced by GO:0002753

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• MONDO:0014367 (1 mention) - the report calls it "Aicardi–Goutières syndrome 7"; MONDO calls it Aicardi-Goutieres syndrome 7
• CL:0000115 (1 mention) - the report calls it "Vascular endothelial cell"; CL calls it endothelial cell
• UBERON:0002420 (1 mention) - the report calls it "Basal ganglia"; UBERON calls it basal ganglion, and lists "basal ganglia" among its other names
• UBERON:0002240 (1 mention) - the report calls it "Spinal cord/corticospinal tracts"; UBERON calls it spinal cord, and lists "spinal cord structure" among its other names
• UBERON:0002097 (1 mention) - the report calls it "Skin"; UBERON calls it skin of body, and lists "skin" among its other names
• UBERON:0002481 (1 mention) - the report calls it "Bone"; UBERON calls it bone tissue, and lists "bone" among its other names
• UBERON:0001091 (1 mention) - the report calls it "Tooth/periodontium"; UBERON calls it calcareous tooth, and lists "tooth" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.